EP-100 Collaboration Lead cancer therapeutic EP-100 is already part of an oncology-focused development program, with an existing strategic alliance with MD Anderson. This creates clear avenues for co-development, licensing, or strategic partnerships with pharma companies seeking novel mechanisms in ovarian and breast cancer. Target business development discussions at corporate development and licensing teams.

GMP Manufacturing Small company size suggests reliance on external manufacturing partners for clinical supply. Position Esperance as a preferred US-based CDMO for GMP synthesis, formulation, and analytical testing of membrane-disrupting peptides for early-phase trials. This aligns with near-term revenue opportunities through clinical material supply contracts.

Strategic Alliances MD Anderson alliance demonstrates readiness to collaborate with major cancer centers; there is potential to broaden the network to other leading institutes to accelerate preclinical and translational work, expand trial sites, and improve patient recruitment.

Advisory Network An active advisory network featuring experienced scientists and a board member strengthens credibility for prospective partners and investors. Leverage Congjian Xu and Mark Pegram as scientific advisors and Brett Giroir on the board to facilitate high-level discussions with potential licensing partners and co-development funders.

Geographic Footprint With a Baton Rouge base and Houston expansion in 2016, the company shows a US-focused footprint that could appeal to near-term regional partnerships and trial logistics. Propose business development outreach to nearby CROs, contract manufacturers, and academic centers to align on timelines for Phase I/II material supply and site activation.